JP2020045367A5 - - Google Patents

Download PDF

Info

Publication number
JP2020045367A5
JP2020045367A5 JP2019230335A JP2019230335A JP2020045367A5 JP 2020045367 A5 JP2020045367 A5 JP 2020045367A5 JP 2019230335 A JP2019230335 A JP 2019230335A JP 2019230335 A JP2019230335 A JP 2019230335A JP 2020045367 A5 JP2020045367 A5 JP 2020045367A5
Authority
JP
Japan
Prior art keywords
orally disintegrating
granule
drug
disintegrating tablet
sucralose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019230335A
Other languages
English (en)
Japanese (ja)
Other versions
JP6847190B2 (ja
JP2020045367A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020045367A publication Critical patent/JP2020045367A/ja
Publication of JP2020045367A5 publication Critical patent/JP2020045367A5/ja
Application granted granted Critical
Publication of JP6847190B2 publication Critical patent/JP6847190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019230335A 2018-06-13 2019-12-20 矯味剤含有顆粒を内在する、服用性が改善された口腔内崩壊錠 Active JP6847190B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018112532 2018-06-13
JP2018112532 2018-06-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019105522A Division JP6639034B2 (ja) 2018-06-13 2019-06-05 矯味剤含有顆粒を内在する、服用性が改善された口腔内崩壊錠

Publications (3)

Publication Number Publication Date
JP2020045367A JP2020045367A (ja) 2020-03-26
JP2020045367A5 true JP2020045367A5 (enExample) 2020-11-05
JP6847190B2 JP6847190B2 (ja) 2021-03-24

Family

ID=69095578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019105522A Active JP6639034B2 (ja) 2018-06-13 2019-06-05 矯味剤含有顆粒を内在する、服用性が改善された口腔内崩壊錠
JP2019230335A Active JP6847190B2 (ja) 2018-06-13 2019-12-20 矯味剤含有顆粒を内在する、服用性が改善された口腔内崩壊錠

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019105522A Active JP6639034B2 (ja) 2018-06-13 2019-06-05 矯味剤含有顆粒を内在する、服用性が改善された口腔内崩壊錠

Country Status (1)

Country Link
JP (2) JP6639034B2 (enExample)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011001487A (es) * 2008-08-08 2011-03-30 Mcneil Ppc Inc Uso de sucralosa como agente granulante.
JP2010202579A (ja) * 2009-03-03 2010-09-16 Sawai Pharmaceutical Co Ltd アカルボースを含有する口腔内崩壊剤
JP5420321B2 (ja) * 2009-06-22 2014-02-19 沢井製薬株式会社 ポラプレジンク含有口腔内崩壊錠
WO2010150221A1 (en) * 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
WO2012042951A1 (ja) * 2010-09-30 2012-04-05 アステラス製薬株式会社 アトルバスタチン含有医薬錠剤
JP5858486B2 (ja) * 2012-05-11 2016-02-10 塩野義製薬株式会社 アスコルビン酸、スクラロースおよびアスパルテームを含有する固形製剤
CN103271888A (zh) * 2013-06-18 2013-09-04 上海奥科达生物医药科技有限公司 普瑞巴林口崩片和分散片及其制备方法
EP3395330B1 (en) * 2015-12-23 2019-10-23 Laboratorios Bagó S.A. Premixture and pharmaceutical composition for the oral administration of memantine as a permanent suspension or prepared prior to administration to the patient, optionally via an enteral feeding tube, and corresponding methods
JP7062368B2 (ja) * 2017-03-15 2022-05-06 武田テバファーマ株式会社 不快な味がマスキングされた経口医薬組成物
JP2019142834A (ja) * 2017-07-31 2019-08-29 大原薬品工業株式会社 プレガバリン並びに好適な賦形剤を含有する固形製剤
JP2019073478A (ja) * 2017-10-17 2019-05-16 日本ケミファ株式会社 4−アミノブタン酸類縁体含有固形製剤及びその製造方法
JP2019147782A (ja) * 2018-02-27 2019-09-05 日本ジェネリック株式会社 プレガバリン含有固形医薬組成物及びその製造法

Similar Documents

Publication Publication Date Title
IL292465B1 (en) Neuroactive compounds and methods of using them
RU2020119391A (ru) Получение тетрациклического соединения, содержащегося в высокой дозе
MX2009003184A (es) Composiciones farmaceuticas que comprenden nilotinib o su sal.
MX2009001294A (es) Granulo y tableta que se desintegra por vía oral que comprende oxicodona.
JP2018162255A5 (enExample)
JP2012031147A5 (enExample)
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
WO2015003478A3 (zh) 一种适用于婴幼儿及儿童的口腔崩解片及其制备方法
JP2015511635A5 (enExample)
RU2014143536A (ru) Фармацевтическая композиция, содержащая омелсартана медоксомил и розувастатин или его соль
HRP20100676T1 (hr) Cvrsti farmaceutski pripravak koji sadrzi benzazepine i postupak njegovog dobivanja
CN110035744A (zh) 一种尼拉帕尼缓控释药物组合物及其用途
JP2014507474A5 (enExample)
JP2016044170A5 (enExample)
JP2018118936A5 (enExample)
JP2018123146A5 (enExample)
MX2018011799A (es) Formas de dosificacion de liberacion prolongada disuasivas de abuso.
HK1214519A1 (zh) 雙用途硫酸鹽口服藥物組合物片劑及其使用方法
EP2591774A4 (en) MELTING TABLET
JP2007063263A5 (enExample)
JP2015120758A5 (enExample)
EA201290055A1 (ru) Новый способ грануляции и полученный с его помощью гранулят
RU2017134562A (ru) Сложный фармацевтический состав, включающий амлодипин, лозартан и хлорталидон
JP2015129175A5 (enExample)
JP2014062064A5 (enExample)